DK2704743T3 - Compositions for inhibiting masp-2 dependent complement acitivation - Google Patents

Compositions for inhibiting masp-2 dependent complement acitivation Download PDF

Info

Publication number: DK2704743T3
Authority: DK; Denmark
Prior art keywords: acitivation; compositions; dependent complement; inhibiting masp; masp
Prior art date: 2011-05-04

Application number

DK12779347.9T

Other languages

English (en)

Inventor

Thomas Dudler

Wayne R Gombotz

James Brian Parent

Clark E Tedford

Anita Kavlie

Urs Beat Hagemann

Herald Reiersen

Sergej Kiprijanov

Original Assignee

Omeros Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-05-04

Filing date

2012-05-04

Publication date

2020-05-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47090380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2704743(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-05-04 Application filed by Omeros Corp filed Critical Omeros Corp

2020-05-25 Application granted granted Critical

2020-05-25 Publication of DK2704743T3 publication Critical patent/DK2704743T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Microbiology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Transplantation (AREA)
Heart & Thoracic Surgery (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Enzymes And Modification Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK12779347.9T 2011-05-04 2012-05-04 Compositions for inhibiting masp-2 dependent complement acitivation DK2704743T3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161482567P	2011-05-04	2011-05-04
PCT/US2012/036509 WO2012151481A1 (en)	2011-05-04	2012-05-04	Compositions for inhibiting masp-2 dependent complement acitivation

Publications (1)

Publication Number	Publication Date
DK2704743T3 true DK2704743T3 (en)	2020-05-25

Family

ID=47090380

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK12779347.9T DK2704743T3 (en)	2011-05-04	2012-05-04	Compositions for inhibiting masp-2 dependent complement acitivation

Country Status (26)

Country	Link
US (6)	US9011860B2 (da)
EP (2)	EP2704743B1 (da)
JP (6)	JP5891298B2 (da)
KR (3)	KR101641057B1 (da)
CN (2)	CN107011443B (da)
AU (1)	AU2012250627B2 (da)
BR (1)	BR112013028429B1 (da)
CA (3)	CA3131223C (da)
CL (1)	CL2013003140A1 (da)
CY (1)	CY1123212T1 (da)
DK (1)	DK2704743T3 (da)
ES (1)	ES2795667T3 (da)
HR (1)	HRP20200887T1 (da)
HU (1)	HUE049154T2 (da)
IL (4)	IL229208B (da)
LT (1)	LT2704743T (da)
ME (1)	ME03755B (da)
MX (3)	MX347691B (da)
PL (1)	PL2704743T3 (da)
PT (1)	PT2704743T (da)
RS (1)	RS60541B1 (da)
RU (3)	RU2636038C2 (da)
SI (1)	SI2704743T1 (da)
SM (1)	SMT202000294T1 (da)
WO (1)	WO2012151481A1 (da)
ZA (1)	ZA201308943B (da)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI2202245T1 (sl)	2007-09-26	2016-10-28	Chugai Seiyaku Kabushiki Kaisha	Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR
TW201447062A (zh)	2008-04-11	2014-12-16	Chugai Pharmaceutical Co Ltd	重複結合複數個抗原的抗原結合分子
TWI812066B (zh)	2010-11-30	2023-08-11	日商中外製藥股份有限公司	具有鈣依存性的抗原結合能力之抗體
MX381987B (es)	2011-04-08	2025-03-13	Univ Leicester	El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2
US9644035B2 (en)	2011-04-08	2017-05-09	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
KR101641057B1 (ko) *	2011-05-04	2016-07-20	오메로스 코포레이션	Masp-2 의존적 보체 활성화를 억제하는 조성물
EP3597747B1 (en)	2012-08-24	2023-03-15	Chugai Seiyaku Kabushiki Kaisha	Mouse fcgammarii-specific fc antibody
EP2912065A4 (en)	2012-10-25	2016-10-19	True North Therapeutics Inc	ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF
JP6543572B2 (ja)	2012-11-02	2019-07-10	バイオベラティブ・ユーエスエイ・インコーポレイテッド	抗補体Ｃ１ｓ抗体とそれらの用途
ES2964340T3 (es) *	2013-03-15	2024-04-05	Omeros Corp	Métodos para generar anticuerpos portadores de péptidos bioactivos y composiciones que comprenden los mismos
US20140363433A1 (en)	2013-03-15	2014-12-11	Omeros Corporation	Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
US11267868B2 (en)	2013-04-02	2022-03-08	Chugai Seiyaku Kabushiki Kaisha	Fc region variant
KR102744762B1 (ko) *	2013-10-17	2024-12-20	오메로스 코포레이션	Masp-2 의존성 보체 활성화와 관련된 상태의 치료 방법
AU2015365168B2 (en)	2014-12-19	2021-08-05	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
CN112142844A (zh) *	2015-02-05	2020-12-29	中外制药株式会社	包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
ES2938359T3 (es)	2015-04-06	2023-04-10	Bioverativ Usa Inc	Anticuerpos humanizados anti-C1s y métodos de uso de los mismos
CN106699888B (zh)	2015-07-28	2020-11-06	上海昀怡健康科技发展有限公司	一种pd-1抗体及其制备方法和应用
KR102432062B1 (ko)	2015-11-09	2022-08-12	오메로스 코포레이션	Masp-2 의존성 보체 활성화와 관련된 질병의 치료 방법
EP3394098A4 (en)	2015-12-25	2019-11-13	Chugai Seiyaku Kabushiki Kaisha	ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
CA3185172A1 (en)	2016-01-05	2017-07-13	Omeros Corporation	Methods for inhibiting fibrosis in a subject in need thereof
KR20250007026A (ko)	2016-03-31	2025-01-13	오메로스 코포레이션	혈관 형성의 억제를 필요로 하는 대상체에서 혈관 형성을 억제하는 방법
JOP20170154B1 (ar) *	2016-08-01	2023-03-28	Omeros Corp	تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
KR102538749B1 (ko)	2016-08-05	2023-06-01	추가이 세이야쿠 가부시키가이샤	Il-8 관련 질환의 치료용 또는 예방용 조성물
JOP20170170B1 (ar) *	2016-08-31	2022-09-15	Omeros Corp	صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JOP20190068A1 (ar) *	2016-10-13	2019-04-01	Omeros Corp	طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي
TWI818919B (zh) *	2017-08-15	2023-10-21	美商歐米諾斯公司	用於治療和／或預防與造血幹細胞移植有關的移植物抗宿主病和／或瀰漫性肺泡出血和／或靜脈閉塞性病的方法
WO2019040453A1 (en) *	2017-08-25	2019-02-28	Omeros Corporation	HIGHLY CONCENTRATED MASP-2 INHIBITOR ANTIBODY FORMULATIONS WITH LOW VISCOSITY, KITS AND METHODS FOR TREATING SUBJECTS SUFFERING FROM ATYPICAL HEMOLYTIC SYNDROME
TW202413402A (zh)	2018-03-15	2024-04-01	日商中外製藥股份有限公司	對茲卡病毒具有交叉反應性的抗登革病毒抗體之用途
EP3802489A4 (en) *	2018-05-29	2022-04-13	Omeros Corporation	MASP -2 INHIBITORS AND METHODS OF USE
US11584714B2 (en)	2018-05-29	2023-02-21	Omeros Corporation	MASP-2 inhibitors and methods of use
PT3893924T (pt) *	2018-12-13	2024-10-09	argenx BV	Anticorpos contra o fator c2b do complemento humano e métodos de utilização
AU2020391175A1 (en) *	2019-11-26	2022-07-07	Omeros Corporation	Methods for treating and/or preventing idiopathic pneumonia syndrome (IPS) and/or capillary leak syndrome (CLS) and/or engraftment syndrome (ES) and/or fluid overload (FO) associated with hematopoietic stem cell transplant
BR112022010890A2 (pt)	2019-12-04	2022-08-16	Omeros Corp	Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado a serina protease-2 associada à lectina de ligação ao manan
US11661418B2 (en)	2019-12-04	2023-05-30	Omeros Corporation	MASP-2 inhibitors and methods of use
WO2021113698A1 (en)	2019-12-04	2021-06-10	Omeros Corporation	Masp-2 inhibitors and methods of use
BR112022010895A2 (pt)	2019-12-04	2022-09-06	Omeros Corp	Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan
TWI834025B (zh) *	2020-03-06	2024-03-01	美商奥默羅斯公司	用於治療和/或預防冠狀病毒誘導的急性呼吸窘迫症候群的抑制masp-2的方法
IL303794A (en) *	2020-12-16	2023-08-01	Keymed Biosciences Co Ltd	Development and application of complement inhibitor
JP2024509702A (ja) *	2021-02-05	2024-03-05	オメロスコーポレーション	急性ｃｏｖｉｄ－１９および急性後ｃｏｖｉｄ－１９を発症するリスクを評価するためのバイオマーカー
CN115215937B (zh) *	2021-04-15	2023-05-26	上海麦济生物技术有限公司	抗人masp-2抗体及其制备方法和应用
TW202305010A (zh)	2021-04-25	2023-02-01	大陸商江蘇恆瑞醫藥股份有限公司	抗ｍａｓｐ２抗體、其抗原結合片段及醫藥用途
TWI863052B (zh) *	2021-12-10	2024-11-21	美商歐米諾斯公司	結合ｍａｓｐ－２的絲氨酸蛋白酶結構域的治療性抗體及其用途
WO2023103789A1 (zh) *	2021-12-10	2023-06-15	舒泰神（北京）生物制药股份有限公司	特异性识别masp2的抗体及其应用
CN116284412A (zh) *	2021-12-21	2023-06-23	沈阳三生制药有限责任公司	一种抗masp-2抗体及其制备方法与用途
WO2023174039A1 (en) *	2022-03-18	2023-09-21	Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd.	Masp-2-targetting antibodies and uses thereof
US20240228499A1 (en)	2022-11-30	2024-07-11	Omeros Corporation	Masp-2 inhibitors and methods of use
US12216123B2 (en)	2023-04-25	2025-02-04	Nuvance Health	Extracellular vesicle derived MASP-2 directed cancer treatment methods

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5211657A (en)	1988-11-07	1993-05-18	The United States Government As Represented By The Secretary Of The Department Of Health And Human Services	Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5549910A (en)	1989-03-31	1996-08-27	The Regents Of The University Of California	Preparation of liposome and lipid complex compositions
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
JP3218637B2 (ja)	1990-07-26	2001-10-15	大正製薬株式会社	安定なリポソーム水懸濁液
JP2958076B2 (ja)	1990-08-27	1999-10-06	株式会社ビタミン研究所	遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5856121A (en)	1994-02-24	1999-01-05	Case Western Reserve University	Growth arrest homebox gene
JPH07238100A (ja)	1994-02-25	1995-09-12	Sumitomo Electric Ind Ltd	ヒトのｍａｓｐに対するモノクローナル抗体
US5741516A (en)	1994-06-20	1998-04-21	Inex Pharmaceuticals Corporation	Sphingosomes for enhanced drug delivery
AU4467396A (en)	1994-12-12	1996-07-10	Omeros Medical Systems, Inc.	Irrigation solution and method for inhibition of pain, inflammation and spasm
US5795587A (en)	1995-01-23	1998-08-18	University Of Pittsburgh	Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en)	1995-07-18	1998-04-14	Lipogenics Ltd.	Liposome compositions and kits therefor
US7083786B2 (en)	1997-04-03	2006-08-01	Jensenius Jens Chr	MASP-2, a complement-fixing enzyme, and uses for it
EP1140171A4 (en)	1998-12-15	2002-03-13	Brigham & Womens Hospital	METHODS AND PRODUCTS FOR REGULATING THE COMPLEMENT ACTIVATION ASSOCIATED WITH THE LECTIN COMPLEMENT SYSTEM
EP1200127B1 (en)	1999-07-21	2008-06-25	Omeros Corporation	Solutions and methods for inhibition of pain, inflammation and cartilage degradation
US20010051754A1 (en)	1999-08-03	2001-12-13	Daria N. Lissy	Plural stage toluene disproportionation process minimizing ethylbenzene
CA2401652A1 (en) *	2000-03-01	2001-09-07	Medimmune, Inc.	High potency recombinant antibodies and method for producing them
SG98393A1 (en)	2000-05-19	2003-09-19	Inst Materials Research & Eng	Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
WO2002006460A2 (en) *	2000-07-13	2002-01-24	Jens Christian Jensenius	Masp-2, a complement-fixing enzyme, and uses for it
EP1300419B1 (en)	2001-10-05	2007-06-13	Affimed Therapeutics AG	Antibody of human origin for inhibiting thrombocyte aggregation
EP3698626A1 (en) *	2001-11-30	2020-08-26	Amgen Fremont Inc.	Transgenic animals bearing human ig lambda light chain genes
MXPA04007124A (es)	2002-02-01	2004-10-29	Omeros Corp	Composiciones y metodos para la inhibicion sistemica de la degradacion del cartilago.
EP1531757B1 (en)	2002-07-19	2016-09-07	Omeros Corporation	Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
EP1598419A1 (en) *	2003-02-28	2005-11-23	Mitsubishi Pharma Corporation	Monoclonal antibody, gene encoding the same, hybridoma, medicinal composition and diagnostic reagent
PL1625166T3 (pl) *	2003-05-12	2015-08-31	Helion Biotech Aps	Przeciwciała przeciwko masp-2
WO2005123776A1 (en) *	2004-06-10	2005-12-29	Omeros Corporation	Methods for treating conditions associated with lectin-dependent complement activation
GB0412966D0 (en)	2004-06-10	2004-07-14	Univ Leicester	Genetically modified non-human mammals and cells
TR201708554T4 (tr)	2004-06-10	2019-02-21	Omeros Corp	Masp-2 ye bağlı tamamlayıcı aktivasyon ile ilişkili durumların tedavisi için yöntemler.
US7919094B2 (en) *	2004-06-10	2011-04-05	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en)	2004-06-10	2014-09-23	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
KR20110057244A (ko)	2008-09-19	2011-05-31	메디뮨 엘엘씨	Ｄｌｌ4에 대한 항체 및 이의 용도
EP2356146A1 (en) *	2008-11-07	2011-08-17	Fabrus Llc	Anti-dll4 antibodies and uses thereof
HUE030897T2 (en) *	2009-10-16	2017-06-28	Omeros Corp	Procedures for Treatment of Disseminated Intravascular Coagulation by Inhibition of MASP-Dependent Complement Activation
KR101641057B1 (ko) *	2011-05-04	2016-07-20	오메로스 코포레이션	Masp-2 의존적 보체 활성화를 억제하는 조성물
KR102318623B1 (ko) *	2012-04-06	2021-11-02	오메로스 코포레이션	발작성 야간혈색뇨증의 치료를 위해 masp-1, masp-2 및/또는 masp-3를 억제하는 조성물 및 방법

2012
- 2012-05-04 KR KR1020137032078A patent/KR101641057B1/ko active Active
- 2012-05-04 CN CN201710201126.9A patent/CN107011443B/zh active Active
- 2012-05-04 RS RS20200685A patent/RS60541B1/sr unknown
- 2012-05-04 KR KR1020187021028A patent/KR102024016B1/ko active Active
- 2012-05-04 CA CA3131223A patent/CA3131223C/en active Active
- 2012-05-04 HU HUE12779347A patent/HUE049154T2/hu unknown
- 2012-05-04 ES ES12779347T patent/ES2795667T3/es active Active
- 2012-05-04 SM SM20200294T patent/SMT202000294T1/it unknown
- 2012-05-04 JP JP2014509474A patent/JP5891298B2/ja active Active
- 2012-05-04 AU AU2012250627A patent/AU2012250627B2/en active Active
- 2012-05-04 PT PT127793479T patent/PT2704743T/pt unknown
- 2012-05-04 BR BR112013028429-3A patent/BR112013028429B1/pt active IP Right Grant
- 2012-05-04 CA CA2832871A patent/CA2832871C/en active Active
- 2012-05-04 RU RU2013153527A patent/RU2636038C2/ru active
- 2012-05-04 EP EP12779347.9A patent/EP2704743B1/en active Active
- 2012-05-04 US US13/464,334 patent/US9011860B2/en active Active
- 2012-05-04 DK DK12779347.9T patent/DK2704743T3/da active
- 2012-05-04 EP EP19215429.2A patent/EP3725811A3/en active Pending
- 2012-05-04 KR KR1020167018831A patent/KR101882830B1/ko active Active
- 2012-05-04 SI SI201231793T patent/SI2704743T1/sl unknown
- 2012-05-04 WO PCT/US2012/036509 patent/WO2012151481A1/en active Application Filing
- 2012-05-04 MX MX2013012862A patent/MX347691B/es active IP Right Grant
- 2012-05-04 CA CA3025762A patent/CA3025762C/en active Active
- 2012-05-04 LT LTEP12779347.9T patent/LT2704743T/lt unknown
- 2012-05-04 CN CN201280032866.XA patent/CN103687620B/zh active Active
- 2012-05-04 MX MX2017006060A patent/MX361175B/es unknown
- 2012-05-04 ME MEP-2020-121A patent/ME03755B/me unknown
- 2012-05-04 PL PL12779347T patent/PL2704743T3/pl unknown
- 2012-11-03 IL IL229208A patent/IL229208B/en active IP Right Grant
2013
- 2013-10-30 CL CL2013003140A patent/CL2013003140A1/es unknown
- 2013-11-03 IL IL229208A patent/IL229208A0/en unknown
- 2013-11-04 MX MX2018014714A patent/MX2018014714A/es unknown
- 2013-11-27 ZA ZA2013/08943A patent/ZA201308943B/en unknown
2015
- 2015-03-17 US US14/660,040 patent/US9475885B2/en active Active
- 2015-09-09 JP JP2015177337A patent/JP6352226B2/ja active Active
2016
- 2016-09-13 US US15/263,876 patent/US10047165B2/en active Active
2017
- 2017-10-31 RU RU2017137872A patent/RU2725958C2/ru active
2018
- 2018-04-04 JP JP2018072245A patent/JP6669800B2/ja active Active
- 2018-07-13 US US16/034,896 patent/US10683367B2/en active Active
2019
- 2019-05-20 IL IL266756A patent/IL266756B/en unknown
2020
- 2020-02-27 JP JP2020031661A patent/JP2020097630A/ja not_active Withdrawn
- 2020-04-24 US US16/857,558 patent/US11613589B2/en active Active
- 2020-06-02 HR HRP20200887TT patent/HRP20200887T1/hr unknown
- 2020-06-10 CY CY20201100525T patent/CY1123212T1/el unknown
- 2020-06-22 RU RU2020120539A patent/RU2020120539A/ru unknown
2021
- 2021-08-10 IL IL285522A patent/IL285522A/en unknown
2022
- 2022-09-02 JP JP2022139872A patent/JP2022172275A/ja not_active Withdrawn
2023
- 2023-02-13 US US18/168,192 patent/US20240092938A1/en active Pending
2024
- 2024-09-10 JP JP2024156933A patent/JP2024170616A/ja active Pending

Also Published As

Publication number	Publication date
US10683367B2 (en)	2020-06-16
US20190119402A1 (en)	2019-04-25
JP2018123148A (ja)	2018-08-09
WO2012151481A1 (en)	2012-11-08
CA2832871A1 (en)	2012-11-08
IL229208B (en)	2021-03-25
ME03755B (me)	2021-04-20
HUE049154T2 (hu)	2020-09-28
PL2704743T3 (pl)	2020-08-24
EP2704743A1 (en)	2014-03-12
US9011860B2 (en)	2015-04-21
US11613589B2 (en)	2023-03-28
AU2012250627B2 (en)	2016-01-07
SMT202000294T1 (it)	2020-07-08
JP6352226B2 (ja)	2018-07-04
CA3131223A1 (en)	2012-11-08
JP6669800B2 (ja)	2020-03-18
AU2012250627A1 (en)	2013-03-21
NZ733310A (en)	2021-12-24
CA3025762A1 (en)	2012-11-08
JP2014515922A (ja)	2014-07-07
CA3025762C (en)	2021-11-09
IL266756B (en)	2021-08-31
ES2795667T3 (es)	2020-11-24
US9475885B2 (en)	2016-10-25
KR20140006096A (ko)	2014-01-15
KR20180086298A (ko)	2018-07-30
PT2704743T (pt)	2020-06-17
EP2704743A4 (en)	2014-11-05
RU2725958C2 (ru)	2020-07-07
EP3725811A2 (en)	2020-10-21
US20240092938A1 (en)	2024-03-21
JP2020097630A (ja)	2020-06-25
CN107011443A (zh)	2017-08-04
CA3131223C (en)	2024-01-30
US10047165B2 (en)	2018-08-14
KR102024016B1 (ko)	2019-11-04
IL285522A (en)	2021-09-30
RS60541B1 (sr)	2020-08-31
HRP20200887T1 (hr)	2020-09-04
BR112013028429A2 (pt)	2020-07-21
CL2013003140A1 (es)	2014-05-23
JP2024170616A (ja)	2024-12-10
US20210054099A1 (en)	2021-02-25
BR112013028429B1 (pt)	2022-11-08
IL266756A (en)	2019-07-31
JP2022172275A (ja)	2022-11-15
JP5891298B2 (ja)	2016-03-22
CA2832871C (en)	2019-01-15
NZ715226A (en)	2017-07-28
CN103687620A (zh)	2014-03-26
MX2013012862A (es)	2013-12-02
NZ617487A (en)	2016-03-31
RU2020120539A (ru)	2021-12-23
US20160002349A1 (en)	2016-01-07
MX347691B (es)	2017-05-09
RU2017137872A (ru)	2019-04-30
CN107011443B (zh)	2021-04-30
KR101882830B1 (ko)	2018-07-31
KR20160087917A (ko)	2016-07-22
MX2018014714A (es)	2021-11-16
EP2704743B1 (en)	2020-03-11
KR101641057B1 (ko)	2016-07-20
CN103687620B (zh)	2017-10-13
MX361175B (es)	2018-11-29
JP2015227380A (ja)	2015-12-17
RU2636038C2 (ru)	2017-11-17
US20120282263A1 (en)	2012-11-08
RU2013153527A (ru)	2015-06-10
LT2704743T (lt)	2020-09-10
CY1123212T1 (el)	2021-10-29
ZA201308943B (en)	2015-05-27
IL229208A0 (en)	2014-01-30
RU2017137872A3 (da)	2019-04-30
US20170088632A1 (en)	2017-03-30
SI2704743T1 (sl)	2020-08-31
EP3725811A3 (en)	2021-01-27

Publication	Publication Date	Title
DK2704743T3 (en)	2020-05-25	Compositions for inhibiting masp-2 dependent complement acitivation
HK1203403A1 (en)	2015-10-30	Peracid-generating compositions
HK1192578A1 (zh)	2014-08-22	抗結皮組合物
SG11201401335QA (en)	2014-05-29	Compositions
GB201117619D0 (en)	2011-11-23	Compositions
GB201117621D0 (en)	2011-11-23	Compositions
GB2496447B (en)	2015-04-22	Compositions
GB201110833D0 (en)	2011-08-10	Compositions
GB201103942D0 (en)	2011-04-20	Compositions
HK1201687A1 (en)	2015-09-11	Improved compositions
PL2717690T3 (pl)	2020-11-02	Kompozycje okulistyczne
GB201110132D0 (en)	2011-07-27	compositions
GB201104849D0 (en)	2011-05-04	Compositions
GB201122214D0 (en)	2012-02-01	Compositions
GB201122216D0 (en)	2012-02-01	Compositions
GB201122213D0 (en)	2012-02-01	Compositions
GB201121028D0 (en)	2012-01-18	Compositions
GB201120406D0 (en)	2012-01-11	Compositions
GB201117234D0 (en)	2011-11-16	Compositions
GB201117165D0 (en)	2011-11-16	Compositions
GB201114629D0 (en)	2011-10-05	Compositions
GB201109121D0 (en)	2011-07-13	Compositions
GB201108338D0 (en)	2011-06-29	Compositions
GB201107998D0 (en)	2011-06-29	Compositions
GB201108040D0 (en)	2011-06-29	Compositions